Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Novo-Helisen Depot
- Development stage
- Phase 4
- Lead developer
- Allergopharma
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Novo-Helisen Depot is a standardized allergen-specific immunotherapy (AIT) product line developed by Allergopharma (a Dermapharm company). It consists of specific allergen extracts—such as house dust mites (*Dermatophagoides pteronyssinus* and *D. farinae*), pollens, or molds (*Alternaria alternata*)—adsorbed onto aluminum hydroxide to create a depot effect. This formulation allows for the sustained release of allergens following subcutaneous injection, facilitating the induction of peripheral immune tolerance. The treatment is indicated for IgE-mediated allergic conditions, including allergic rhinitis, allergic conjunctivitis, and allergic bronchial asthma, in both children and adults. The therapeutic goal is to desensitize the patient's immune system, shifting the response from a pro-inflammatory Th2 profile toward a regulatory T-cell (Treg) and Th1 profile, thereby reducing clinical symptoms and the requirement for symptomatic medication.
- Brand names
- Novo-Helisen Depot
- Other names
- NHDNHD3NHD-3NHD 3Novo-Helisen Depot Strengths 1 to 3Novo-Helisen Depot 100%
Beyond the preview
Go deeper on Novo-Helisen Depot.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novo-Helisen Depot.